| 8379- | LT, | Luteolin and neuroinflammation: a multi-target therapeutic strategy for central nervous system disorders |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 8378- | LT, | Luteolin and its derivatives: modulation of epithelial-mesenchymal transition in fibrosis and cancer |
| - | Review, | Var, | NA |
| 8372- | LT, | Luteolin targets peroxiredoxin 2 to augment T-cell-mediated cytotoxicity and suppress lung adenocarcinoma progression |
| - | in-vitro, | Lung, | NA |
| 8387- | LT, | QC, | Api, | Ba, | Identification of Flavonoid Compounds in Treating Alzheimer's Disease Based on Network Medicine Framework Strategy |
| - | in-vitro, | AD, | NA |
| 8388- | LT, | Untargeted metabolomics reveals the mechanisms of luteolin and exercise combination treatment against cognitive impairments in AD mice through modulating autophagy |
| - | in-vivo, | AD, | NA |
| 8389- | LT, | Luteolin-Manganese Nanozyme Induces Apoptosis and Ferroptosis for Enhanced Cancer Therapy |
| - | in-vitro, | Var, | NA |
| 8390- | LT, | Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease Continuum Perspective |
| - | Review, | IBD, | NA | - | Review, | CRC, | NA |
| 8391- | LT, | Mechanism of luteolin against non-small-cell lung cancer: a study based on network pharmacology, molecular docking, molecular dynamics simulation, and in vitro experiments |
| - | in-vitro, | NSCLC, | NA |
| 8392- | LT, | Revisiting Luteolin Against the Mediators of Human Metastatic Colorectal Carcinoma: A Biomolecular Approach |
| - | in-vitro, | CRC, | HCT15 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Nor, | RWPE-1 |
| 8393- | LT, | Progress, pharmacokinetics and future perspectives of luteolin modulating signaling pathways to exert anticancer effects: A review |
| - | Review, | Var, | NA |
| 8394- | LT, | Luteolin prevents THP-1 macrophage pyroptosis by suppressing ROS production via Nrf2 activation |
| - | in-vitro, | Nor, | NA |
| 8395- | LT, | PacT, | Luteolin enhances drug chemosensitivity by downregulating the FAK/PI3K/AKT pathway in paclitaxel‑resistant esophageal squamous cell carcinoma |
| - | in-vitro, | ESCC, | NA |
| 8396- | LT, | Myr, | KAE, | QC, | Api | Antiplatelet Effects of Flavonoid Aglycones Are Mediated by Activation of Cyclic Nucleotide-Dependent Protein Kinases |
| - | in-vivo, | Nor, | NA |
| 8375- | LT, | Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches |
| - | Review, | Var, | NA |
| 8406- | LT, | Cisplatin, | Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase–mediated p53 phosphorylation and stabilization |
| - | vitro+vivo, | Liver, | HepG2 | - | in-vitro, | Laryn, | HEp2 |
| 8405- | LT, | Rad, | Luteolin's role as a radiosensitizer by promoting cell death and ROS modulation |
| - | Review, | NSCLC, | NA |
| 8403- | LT, | Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells |
| - | in-vitro, | CRC, | HT-29 |
| 8402- | LT, | Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway |
| - | vitro+vivo, | CRC, | T24/HTB-9 |
| 8401- | LT, | Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis |
| - | Review, | Var, | NA |
| 8400- | LT, | Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling |
| - | in-vitro, | BC, | NA |
| - | in-vivo, | AD, | NA |
| 8398- | LT, | Luteolin: Nature's promising warrior against Alzheimer's and Parkinson's disease |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 8366- | LT, | Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance |
| - | Trial, | Pca, | NA |
| 8367- | LT, | Role of Luteolin in Prevention of Oral, Esophageal, Gastric, Pancreatic, and Colon Cancers: Recent Trends and Future Perspectives |
| - | Review, | Var, | NA |
| 8368- | LT, | A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | NA |
| 8369- | LT, | Luteolin inhibits proliferation of lung cancer A549 cells by increasing ROS production and inhibiting the AKT/mTOR signaling pathway and HO-1 expression |
| - | in-vitro, | Lung, | A549 |
| 8370- | LT, | Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer |
| - | vitro+vivo, | Colon, | NA |
| 8371- | LT, | Study on the regulatory mechanism of luteolin inhibiting WDR72 on the proliferation and metastasis of non small cell lung cancer |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Nor, | BEAS-2B |
| 8373- | LT, | ATV, | Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models |
| - | in-vivo, | Nor, | NA |
| - | in-vitro, | Nor, | NA |
| 8376- | LT, | Cisplatin, | Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization |
| - | vitro+vivo, | Var, | NA |
| 7825- | LT, | MBS, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA |
| 1064- | LT, | Cisplatin, | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells |
| - | vitro+vivo, | Lung, | LNM35 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 1125- | LT, | Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity |
| - | in-vitro, | BC, | NA |
| 1060- | LT, | BTZ, | Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma |
| - | vitro+vivo, | Melanoma, | NA |
| 1084- | LT, | CHr, | Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells |
| - | in-vitro, | Nor, | RAW264.7 |
| 1100- | LT, | Luteolin, a flavonoid, as an anticancer agent: A review |
| - | Review, | NA, | NA |
| 986- | LT, | doxoR, | Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF7 |
| 982- | LT, | Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19) |
| - | in-vitro, | Ovarian, | KGN |
| 973- | LT, | Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 |
| 979- | LT, | Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 |
| 4339- | LT, | Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis |
| - | in-vivo, | NA, | NA |
| 4338- | LT, | Luteolin: a natural product with multiple mechanisms for atherosclerosis |
| - | Review, | NA, | NA |
| 4295- | LT, | Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury |
| - | in-vivo, | AD, | NA |
| 4294- | LT, | Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells |
| - | in-vitro, | NA, | SH-SY5Y |
| 4293- | LT, | Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin |
| - | in-vivo, | Diabetic, | NA |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 4232- | LT, | Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder |
| - | in-vivo, | NA, | NA |
| 4231- | LT, | Luteolin and its antidepressant properties: From mechanism of action to potential therapeutic application |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid